Tag: ordinary

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- The Boards of Trustees/Directors of the PIMCO closed-end funds below (each, a “Fund” and, collectively, the “Funds”) have declared a monthly distribution for each Fund’s common shares as summarized below.

Volta Finance Limited (VTA/VTAS)

Selangor, Malaysia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Empro Group Inc. (the “Company” or “EMPG”), a rising beauty and personal care brand headquartered in Malaysia, today announced that it closed the sales of an additional 91,250 ordinary shares of the Company, representing the exercise of the remaining portion of the underwriter’s over-allotment option granted in connection with the Company’s initial public offering (the “IPO”, and together with such over-allotment closing, the “Offering”), at the IPO price of $4.00 per share, less underwriting discounts. As a result, the Company has raised gross proceeds of $365,000 in addition to the previously announced IPO gross proceeds of approximately $5,500,000 and the previously announced gross proceeds of $460,000 arising from the partial exercise by the underwriter of its over-allotment option that closed on July 30, 2025, for aggregate gross of proceeds of $6,325,000, before deducting underwriting discounts and other offering expenses.

LEI: 213800NNT42FFIZB1T09
01 August 2025

STAMFORD, CT, July 31, 2025 (GLOBE NEWSWIRE) -- HCM III Acquisition Corp. (the “Company”), a blank check company whose business purpose is to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses, announced today that it has priced its initial public offering of 22,000,000 units at $10.00 per unit. Each unit consists of one Class A ordinary share and one-third of one redeemable warrant. The units will be listed on the Nasdaq Global Market (“Nasdaq”) and will begin trading tomorrow, August, 1, 2025, under the ticker symbol “HCMAU." Each whole warrant is exercisable to purchase one Class A ordinary share of the Company at a price of $11.50 per share. Only whole warrants are exercisable and will trade. Once the securities comprising the units begin separate trading, the Class A ordinary shares and warrants are expected to be listed on the Nasdaq under the symbols “HCMA” and “HCMAW,” respectively.

Cayman Islands, July 31, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech company developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 152,106 of the Company’s ordinary shares originally issued in January 2025 at a reduced exercise price of $11.57 per share. The ordinary shares issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-282932) and an effective resale registration statement on Form S-1 (No. 333-284873). The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $1.8 million, prior to deducting placement agent fees and estimated offering expenses. The offering is expected to close on or about August 1, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering as working capital for general corporate purposes.

Reports Adjusted EBITDAS of $9.6 million, representing a 16% improvement from prior year